dr. rudin on the design of the keynote-604 trial in es-sclc
Published 4 years ago • 90 plays • Length 1:02Download video MP4
Download video MP3
Similar videos
-
5:02
researcher comment: the keynote-604 trial | charles rudin
-
2:47
charles rudin, md, phd, shares outcomes of the keynote 604 study to investigating keytruda and chemo
-
0:53
charles rudin, md, phd, discusses the keynote-604 study and the role of keytruda in es-sclc
-
0:46
charles rudin, md, phd, shares the take home message regarding keynote-604 for lung cancer treatment
-
4:57
chemoimmunotherapy for es sclc: caspian trial
-
1:36
dr. rudin on expansion of immunotherapy in lung cancer
-
1:15
dr. rudin discusses the success of immunotherapy in sclc
-
0:54
dr. rudin on caveats of the keynote-021 in patients with nsclc
-
4:20
keynote-604: pembrolizumab plus etoposide and platinum as a first-line therapy for extensive-sta...
-
1:41
dr. rudin on rova-t in patients with small cell lung cancer
-
2:17
small cell lung cancer: future directions in care
-
1:20
dr. charles rudin: immunotherapy for small cell lung cancer
-
1:29
dr. charles rudin: changing the tide in lung cancer research funding
-
1:11
dr charles rudin: changing the tide in funding for lung cancer research
-
1:01
dr. rudin on immunotherapy biomarkers in lung cancer
-
1:23
dr. liu on the potential of pembrolizumab in sclc
-
3:02
dr. ou on the fda approval of pembrolizumab in sclc
-
8:19
keynote trial data: pembrolizumab’s role in nsclc
-
1:22
updated outcomes of keynote-010 of pembrolizumab for nsclc